Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
NASDAQ:CMRX
CMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.75 - $8.54
Previous CloseN/A
Volume622.27K
Average Volume (3M)6.45M
Market Cap
$799.21M
Enterprise Value$183.64M
Total Cash (Recent Filing)$19.91M
Total Debt (Recent Filing)$14.62M
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
May 01, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding93,803,850
10 Day Avg. Volume1,883,496
30 Day Avg. Volume6,449,108
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4807.90
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit866.25
Enterprise Value/Ebitda-1.90
Forecast
1Y Price Target
$8.54Price Target Upside0.35% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
Chimerix News
See All CMRX News
---
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition agreement between Chimerix and Jazz Pharmaceuticals is expected to close in a timely manner.
Product PotentialDordaviprone, the lead drug in phase III trials, is seen as having the potential to become the standard of care with durable revenues into 2037.
Regulatory ApprovalThe FDA has accepted Chimerix's NDA with priority review status for dordaviprone, indicating a strong potential for approval.
Bears Say
Analyst RecommendationThe recommendation for Chimerix stock has been downgraded from BUY to HOLD.
Financial PerformanceChimerix reported 4Q24 GAAP EPS of ($0.26) and non-GAAP EPS of ($0.25), both slightly below estimates.
Financial SustainabilityThe company's estimated cash burn for the fiscal year is $98 million, suggesting a significant outflow of cash.
---
Ownership Overview
5.91% Insiders
6.65% Mutual Funds
30.53% Other Institutional Investors
52.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMRX FAQ
What was Chimerix’s price range in the past 12 months?
Chimerix lowest stock price was $0.75 and its highest was $8.54 in the past 12 months.
What is Chimerix’s market cap?
Chimerix’s market cap is $799.21M.
When is Chimerix’s upcoming earnings report date?
Chimerix’s upcoming earnings report date is May 01, 2025 which is in 21 days.
How were Chimerix’s earnings last quarter?
Chimerix released its earnings results on Mar 21, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.01.
Is Chimerix overvalued?
According to Wall Street analysts Chimerix’s price is currently Undervalued.
Does Chimerix pay dividends?
Chimerix does not currently pay dividends.
What is Chimerix’s EPS estimate?
Chimerix’s EPS estimate is -0.26.
How many shares outstanding does Chimerix have?
Chimerix has 93,803,850 shares outstanding.
What happened to Chimerix’s price movement after its last earnings report?
Chimerix reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went up 0.354%.
Which hedge fund is a major shareholder of Chimerix?
Currently, no hedge funds are holding shares in CMRX
---
Chimerix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.54 (0.35% Upside)
$8.54 (0.35% Upside)
Blogger Sentiment
Bullish
CMRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 15.8%
Last 30 Days ▼ 15.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
751.00%
12-Months-Change
Fundamentals
Return on Equity
-56.17%
Trailing 12-Months
Asset Growth
-31.38%
Trailing 12-Months
Company Description
Chimerix
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
---
CMRX Stock 12 Month Forecast
Average Price Target
$8.54
▲(0.35% Upside)
Technical Analysis
BioCryst
―
SIGA Technologies
―
Sarepta Therapeutics
―
Akebia Therapeutics
―
Vir Biotechnology
―
Best Analysts Covering CMRX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
+131.52%
reiterated a buy rating 8 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of +131.52% per trade.
---